Avivagen Announces Investor Conference Attendance In British Columbia, Canada July 17-19

Avivagen Inc.

Healthcare & Pharmaceutical

Share Tweet

Avivagen Announces Investor Conference Attendance In British Columbia, Canada July 17-19

Ottawa, ON / ACCESSWIRE / Jul 16 2014 / - Avivagen Inc. (TSXV: VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces that it will be attending an investor conference in the Canadian province of British Columbia.

The investor conference has been organized by Pathfinder Asset Management (Pathfinder) and will take place from July 17-19, 2014 in the city of Kelowna. Pathfinder is an independent boutique investment company based in Vancouver and is a shareholder of Avivagen. Further information about Pathfinder is available at www.paml.ca.

The investor conference is by invitation only and directly links public issuers with brokers and others through a day long series of twenty minute one-on-one meetings. The conference is a non-deal focused event specifically targeting the best brokers that Pathfinder deals with, analysts they listen to and other funds that they talk to. This event is designed to provide investment brokers, analysts and fund managers with a unique opportunity to gain insight into emerging growth companies across a variety of sectors, including Business Services, Consumer, Cleantech, Gaming, Healthcare and Technology & Media. Further information about the conference is available at http://www.capitaleventmanagement.ca/pathfinderconference/index.html

Avivagen's CEO, Cameron Groome, is scheduled for a full day of meetings on Friday, July 18th, 2014. The meetings will start at 10:00 AM Pacific Time (UTC-08:00) and each meeting will be of 20 minutes duration. The corporate PowerPoint presentation to which Mr. Groome will be speaking will be posted to the Avivagen website at 8:00 AM Eastern Time that morning.

Attendance at such investor conferences provides a forum to communicate with shareholders. Effective shareholder communications helps to optimize the trading liquidity of Avivagen's shares and to ensure their efficient valuation by capital markets.

About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV". The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and production animals by employing natural mechanisms for maintaining good health. Avivagen's targeted markets include Livestock Productivity and Pet Wellness.

The company has sites located in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. More information can be found at www.avivagen.com.

About OxC-beta

Avivagen's proprietary and patent-protected technology is based on its discoveries concerning carotenoid antioxidants. The novel natural compounds discovered by Avivagen support the body's own systems to maintain and enhance health, particularly by supporting immune function. Avivagen's commercial-stage application of its technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.

Research results indicate OxC-beta supports innate immune function, which can help maintain good health. In pets, OxC-beta supports overall vitality and energy, mobility and joint function, skin, coat and gut. Results observed in food animals have included healthier growth, better utilization of feed and decreased mortality. In food animals, it is intended that use of OxC-beta avoids the feeding of antibiotics.

The commercial products of Avivagen are OxC-beta for livestock, Vivamune(TM) Health Chews and Oximunol(TM) Chewables.

About OxC-beta for Livestock

OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to animal feeds, in accordance with producer-developed protocols. In past studies, OxC-beta has been shown to support health or growth in species such as fish, chicken, pigs and cattle. OxC-beta for livestock is currently available for commercial sale in the Kingdom of Thailand.

About Vivamune(TM) Health Chews - For dogs and cats

Vivamune(TM) Health Chews, containing Avivagen's proprietary active ingredients, are scientifically-formulated chews for dogs and cats. Vivamune(TM) Health Chews work with a pet's own immune system to maintain overall health and well-being. They are sold in re-sealable packages of 30 chews and are currently available in the United States by ordering on-line at www.vivamunehealth.com.

About Oximunol(TM) Chewables - For dogs

Oximunol(TM) Chewables are scientifically-formulated chewable tablets that contain Avivagen's proprietary, patented active ingredient OxC-beta. OxC-beta has been shown to stimulate innate cellular immunity and may thereby help to maintain overall health and well-being. Oximunol(TM) Chewables are distributed by Bayer Healthcare LLC and are available through veterinarians for dogs of all ages in the United States.

Permanent Non-Surgical Sterilization of Female Mammals

Avivagen has optioned worldwide exclusive rights to a technology for the permanent and non-surgical sterilization of female mammals. A proof-of-concept trial in an indicative species will soon be started in order to demonstrate whether the technology appears to be safe and effective. It is expected that a patent application covering World Trade Organization countries will be pursued and that technological details will be made available when that patent application is published. Further information will be disclosed as deemed prudent or as required.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipated", "believe", "could", "estimated", "expected", "if", "intended", "likely", "may", "plan", "possibly", "potentially", "should", "whether", "will", "would" and similar expressions. Statements about Avivagen's beliefs about the viability and potential future applications of the technologies described in its corporate presentation, including their novelty and proposed uses, whether or not they are patentable, and whether or not they infringe the intellectual property rights of third parties and statements about their potential markets are all forward looking statements. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events relating to its business generally and the specific subject matters of this news release. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.

Cameron Groome

CEO & President

Phone: 613-949-8164


SOURCE: Avivagen Inc.  

Copyright (C) 2014 Avivagen